98%
921
2 minutes
20
We present a thermal-driven, orthogonally polarized, eye-safe dual-wavelength microchip laser based on an cut Er,Yb:YAl(BO) (Er,Yb:YAB) crystal, operating without the need for additional intracavity elements. Two thermal management schemes were investigated, revealing that additional end-face cooling effectively reduces internal temperature gradients within the crystal. As a result, the laser achieved a total output power of 1.04 W at the polarization intersection point (PIP) and an extended polarization coexistence range (PCR) of up to 11 W, with dual-wavelength emission at 1551.9 nm and 1556.5 nm, corresponding to a frequency difference of 0.57 THz. Furthermore, by adjusting the cooling temperature, both the PIP output power and PCR exhibited an approximately linear dependence, offering a practical means of thermally controlling polarization dynamics. Theoretical simulations showed good agreement with experimental results, confirming the validity of the thermal-driving mechanism. This compact, alignment-free laser architecture holds strong potential for applications in laser interferometry, precision metrology, coherent THz radiation, and eye-safe differential absorption lidar.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1364/OE.565890 | DOI Listing |
We present a thermal-driven, orthogonally polarized, eye-safe dual-wavelength microchip laser based on an cut Er,Yb:YAl(BO) (Er,Yb:YAB) crystal, operating without the need for additional intracavity elements. Two thermal management schemes were investigated, revealing that additional end-face cooling effectively reduces internal temperature gradients within the crystal. As a result, the laser achieved a total output power of 1.
View Article and Find Full Text PDFInt J Nanomedicine
June 2024
Department of Pharmacy, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, 450008, People's Republic of China.
Background: The commercial docetaxel (DTX) formulation causes severe side effects due to polysorbate 80 and ethanol. Novel surfactant-free nanoparticle (NP) systems are needed to improve bioavailability and reduce side effects. However, controlling the particle size and stability of NPs and improving the batch-to-batch variation are the major challenges.
View Article and Find Full Text PDF